Symbols

LUCD

Lucid Diagnostics·NASDAQ

--(--)

LUCD fundamentals

LUCD Q4 2025 Earnings

Lucid Diagnostics (LUCD) released its earnings on Mar 25, 2026: revenue was 1.35M (YoY +12.82%), missed estimates; EPS was -0.09 (YoY +52.63%), beat estimates.

Revenue / YoY

1.35M

+12.82%

EPS / YoY

-0.09

+52.63%

Report date

Mar 25, 2026

LUCD Earnings Call Summary for Q4,2025

Q4 Volume Surge: 29% test volume growth to 3,664, driven by Medicare focus and team productivity.
VA Breakthrough: $1.938M VA contract at Medicare rate, targeting 2-3M high-risk veterans.
Real-World Validation: 95% success rate for EsoCheck in under 2 minutes,优于传统技术。
Reimbursement Momentum: UnitedHealthcare policy shift enables credentialing; first LBM policy pending.
Medicare Imminent: Draft LCD expected, with $2M backlog collection potential.
Financial Caution: $34.7M cash, 10% OpEx growth, 80% uncollected claims highlight risk management.

Earnings

EPS

Revenue

Revenue & Expenses

LUCD has released its 2025 Q4 earnings report, with revenue of 1.50M, reflecting a YoY change of 25.65%, and net profit of -16.27M, showing a YoY change of -40.94%. The Sankey diagram below clearly presents LUCD's revenue sources and cost distribution.

Key Indicators

Lucid Diagnostics (LUCD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lucid Diagnostics (LUCD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lucid Diagnostics (LUCD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lucid Diagnostics (LUCD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown